AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Ataxia-Telangiectasia

Recent research efforts aimed at curing Ataxia-Telangiectasia.

Last updated

Ataxia-Telangiectasia

Overview

Ataxia-telangiectasia (A-T) is a rare inherited condition caused by harmful changes in both copies of the ATM gene, which normally helps cells respond to DNA damage. Classic A-T usually begins in early childhood with worsening problems with balance and coordination, abnormal eye movements, speech difficulty, immune deficiency, lung disease, sensitivity to ionizing radiation, and a high risk of cancer; visible small blood vessels in the eyes and skin often appear later. Prognosis varies, but classic A-T substantially shortens life expectancy, most often because of cancer, lung disease, or severe infections. GeneReviews: Ataxia-Telangiectasia

There is no approved treatment that corrects the underlying ATM defect or cures A-T. Current care is multidisciplinary and supportive: rehabilitation and mobility support, speech and nutrition services, prevention and treatment of respiratory infections, immunoglobulin replacement when indicated, cancer surveillance, and avoidance or careful minimization of radiation exposure. GeneReviews: Ataxia-Telangiectasia

Scope of Recent Research (2020–present)

Research from 2020 through September 9, 2026 has become more precise but remains small relative to the complexity of A-T. The leading curative question is whether enough ATM function can be restored early enough—particularly in the brain and immune system—to prevent or substantially delay irreversible disease; current work spans mutation-specific RNA medicines, difficult gene-delivery platforms, and treatments that may slow symptoms without repairing the gene. The field has reached an early human test of a mutation-targeted antisense drug, but no approach has yet demonstrated a cure. Individualized splice-switching therapy framework GeneReviews: Ataxia-Telangiectasia

Major Breakthroughs and Emerging Therapies

The most important recent advance is mutation-specific antisense oligonucleotide therapy. Antisense oligonucleotides (ASOs) are short synthetic strands of nucleic acid designed to alter how RNA is spliced—the process by which cells assemble a gene’s message before making protein. In a 2023 study of 235 people from 209 A-T families, investigators used whole-genome sequencing and RNA analyses to identify deep-intronic and other variants that might be corrected by splice-switching ASOs. They developed ASOs that restored correct ATM RNA splicing and ATM signaling in patient-derived fibroblasts for two recurrent variants; their framework estimated that 9% of participants had variants probably amenable to this approach and another 6% possibly amenable. Individualized splice-switching therapy framework

One of these medicines, AT008—now called atipeksen—targets the recurrent ATM c.7865C>T variant, which creates abnormal RNA splicing. In the initial individualized clinical use described in the 2023 report, treatment was tolerated without serious adverse events over three years; however, this was a single-child experience and did not establish clinical efficacy or a cure. Individualized splice-switching therapy framework This work is especially significant because it restores signaling from the patient’s own full-length ATM gene rather than attempting to insert an entire replacement gene. Individualized splice-switching therapy framework

Gene addition and gene editing remain preclinical. The ATM coding sequence is unusually large, creating a major packaging problem for commonly used viral vectors. A 2023 vector study tested foamy-virus, lentiviral, and gammaretroviral systems carrying mouse Atm; although expression was achieved, vector production and transduction efficiency dropped sharply with the large cargo, illustrating why a systemic or brain-directed replacement-gene therapy is not yet ready for patients. Large-cargo gene-therapy vectors for A-T A German Research Foundation-supported program is pursuing both foamy-virus delivery of ATM complementary DNA to blood-forming stem cells and correction of A-T mutations by gene editing, but these remain research strategies rather than human A-T treatments. DFG: Hematopoietic stem-cell gene therapy for A-T

Nicotinamide riboside (NR), a vitamin B3-related precursor that raises NAD+, is being studied as a disease-modifying metabolic treatment rather than a genetic cure. In a 2021 open-label proof-of-concept study of 24 people with A-T, ataxia scores improved during four months of NR and worsened after withdrawal; immunoglobulin levels also rose in participants with immune deficiency. NR proof-of-concept study A later two-year single-arm study reported that NR was generally well tolerated and that coordination and eye-movement measures improved or declined more slowly than historical expectations, but the absence of a randomized control group means these findings cannot prove that NR changes the long-term course of A-T. Two-year NR study

Clinical Trials and Experimental Approaches

A Phase 1/2 trial of intrathecal atipeksen, meaning delivery into cerebrospinal fluid, is recruiting up to 10 people with A-T who carry at least one ATM c.7865C>T variant. The investigator-led study associated with Timothy Yu and Boston Children’s Hospital is designed to assess safety and to look for stabilization of neurologic decline using the A-T Neurological Examination Toolkit, structured clinical global-impression measures, wearable movement tracking, brain-volume imaging, neurofilament light chain, alpha-fetoprotein, and growth measures. No efficacy results have been posted. A-T atipeksen Phase 1/2 trial Individualized splice-switching therapy framework

NR has continued in investigator-sponsored studies. The University Hospital, Akershus-sponsored Phase 2 study, NCT04870866, is active but not recruiting and evaluates two years of NR using neurologic, quality-of-life, NAD-metabolite, and laboratory measures. NR Phase 2 trial A separate University of Queensland single-arm NR study, NCT06324877, was listed as not yet recruiting in its last public record update and includes ataxia scales, immune measures, and neurofilament light chain. ATNAD NR study

The most advanced non-genetic program, Quince Therapeutics’ red-blood-cell-encapsulated dexamethasone sodium phosphate (eDSP/EryDex), was not curative and did not succeed in its pivotal trial. On January 29, 2026, Quince reported that its randomized Phase 3 NEAT study of 105 participants did not meet its six-month primary neurologic endpoint or key secondary endpoint and that it would cease eDSP clinical development, despite generally favorable tolerability. NEAT Phase 3 topline results Earlier long-term analyses of EryDex reported relatively limited classic steroid toxicities but iron deficiency, transient itching around infusions, anemia in some participants, and a decline in bone-mineral-density z-score that could not be separated from disease progression. Long-term EryDex safety analysis

Methodologies and Scientific Approaches

A-T cure research increasingly begins with comprehensive molecular diagnosis. Whole-genome sequencing, RNA sequencing, minigene splicing assays, and patient-derived fibroblast experiments can identify variants missed by standard exon-focused testing and test whether an ASO restores normal ATM transcript production and downstream DNA-damage responses, including radiation-induced phosphorylation of p53 and KAP1. Individualized splice-switching therapy framework

Researchers also combine disease models with delivery engineering. Viral-vector teams test whether blood-forming stem cells can receive a functional ATM sequence or a corrected mutation ex vivo, while neurologic trials increasingly use A-T-specific examination tools, video assessments, wearable actigraphy, neurofilament light chain, alpha-fetoprotein, and brain volumetric MRI as potential biomarkers of disease progression or treatment effect. Large-cargo gene-therapy vectors for A-T A-T atipeksen Phase 1/2 trial

Leading Institutions and Funding

Boston Children’s Hospital, Harvard Medical School, the Broad Institute, and the A-T Children’s Project network have been central to the individualized ASO program, including the genomic analysis and early atipeksen treatment work. Individualized splice-switching therapy framework Other visible research centers include the University Hospital, Akershus and Oslo University Hospital in NR studies; the University of Queensland in the ATNAD NR study; and German groups working on hematopoietic stem-cell gene therapy and gene editing. NR Phase 2 trial ATNAD NR study DFG: Hematopoietic stem-cell gene therapy for A-T

Patient-led funding is important because A-T is rare. Publicly reported grant data indicate that the A-T Children’s Project awarded approximately $3.6 million across 27 grants to 13 organizations from 2020 through 2024, including a $600,000 2024 grant to Duke University and earlier support for the Broad Institute, Boston-area hospitals, and translational research contractors. A-T Children’s Project grant record

Strengths, Limitations, and Challenges

The field’s key strength is that A-T is a single-gene disorder with a clear biological target: restoring ATM activity. The ASO work provides direct evidence that selected disease-causing splice defects can be corrected in patient cells and has progressed from genomic screening to human dosing. Individualized splice-switching therapy framework NR studies and eDSP trials have also helped develop practical outcome measures and longer-term safety data in an exceptionally small and medically complex population. Two-year NR study Long-term EryDex safety analysis

The central limitations are formidable. An ASO is mutation-specific and therefore cannot serve everyone with A-T; repeated intrathecal dosing and lifelong safety must be established, and it remains unknown how much ATM restoration is required in the cerebellum, immune system, lungs, and cancer-prone tissues. Individualized splice-switching therapy framework Replacement-gene strategies must solve the large-ATM cargo problem, achieve safe delivery to relevant tissues, and avoid unacceptable DNA damage or cancer risk in cells already deficient in DNA repair. Large-cargo gene-therapy vectors for A-T The NEAT failure also shows that symptomatic improvement signals and long-term tolerability do not guarantee success in a controlled pivotal trial. NEAT Phase 3 topline results

Outlook and Future Directions

As of September 9, 2026, A-T is not close to a universal cure, but it has moved into a more credible precision-medicine era. The decisive near-term milestones are initial safety and biomarker results from the atipeksen Phase 1/2 trial; replication of NR findings in controlled studies; identification of additional ASO-addressable ATM variants; and demonstration that a large-ATM gene-delivery or editing platform can safely restore meaningful function in relevant animal models and, eventually, people. A realistic first transformative outcome is likely to be prevention or major slowing of neurologic decline for genetically defined subgroups, rather than a single one-time therapy that reverses every manifestation of established A-T. A-T atipeksen Phase 1/2 trial Individualized splice-switching therapy framework

References

Don't see your disease? Request a report